Skip to content

Neurocrine Biosciences NBIX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$668.6M+119%$478.6M+40.2%$428M+10.9%$348.3M+2.7%$305.8M-17.3%
$26.6M+7.3%$26M+10.6%$25.8M+16.2%$24.7M+16.5%$24.8M+30.5%
$222.3M+9.1%$217.9M+11.5%$225.7M+35.0%$213.5M+23.1%$203.8M+2.5%
$863.7M+63.0%$782.7M+31.5%$636.8M+33.7%$567.3M+7.0%$529.9M-17.9%
$34.8M-7.7%$36.4M-4.7%$43.7M+20.4%$38.6M+7.8%$37.7M+21.6%
-$784.8M-$264.4M-$279.8M
$467.7M$450M
-$411.2M-143%-$700.9M-652%
$72.4M+136%$480M+2,752%-$8.9M-116%$124.3M+706%-$202.2M
$831.3M+68.9%$748.7M+34.4%$593.1M+34.8%$528.7M+6.9%$492.2M-19.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Neurocrine Biosciences generate?
Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
What is Neurocrine Biosciences's free cash flow?
After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
Where does Neurocrine Biosciences's cash flow data come from?
Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.